[go: up one dir, main page]

WO2012074237A3 - Composition médicinale liquide comprenant du dorzolamide et de la brimonidine pour l'ophtalmologie - Google Patents

Composition médicinale liquide comprenant du dorzolamide et de la brimonidine pour l'ophtalmologie Download PDF

Info

Publication number
WO2012074237A3
WO2012074237A3 PCT/KR2011/008911 KR2011008911W WO2012074237A3 WO 2012074237 A3 WO2012074237 A3 WO 2012074237A3 KR 2011008911 W KR2011008911 W KR 2011008911W WO 2012074237 A3 WO2012074237 A3 WO 2012074237A3
Authority
WO
WIPO (PCT)
Prior art keywords
brimonidine
ophthalmology
salt
liquid medicine
medicine composition
Prior art date
Application number
PCT/KR2011/008911
Other languages
English (en)
Korean (ko)
Other versions
WO2012074237A2 (fr
Inventor
이상용
이근혁
김진선
최병선
양재식
Original Assignee
한림제약(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한림제약(주) filed Critical 한림제약(주)
Publication of WO2012074237A2 publication Critical patent/WO2012074237A2/fr
Publication of WO2012074237A3 publication Critical patent/WO2012074237A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition médicinale liquide comprenant en tant qu'ingrédients actifs du dorzolamide ou un sel de celui-ci, du timolol ou un sel de celui-ci et de la brimonidine ou un sel de celle-ci, pour l'ophtalmologie, composition qui est stable et non-irritante. Plus particulièrement, la présente invention concerne une composition médicinale liquide pour l'ophtalmologie comprenant : 1-3 % p/v de dorzolamide ou son sel ; 0,1-1 % p/v de timolol ou son sel ; 0,1-0,5 % p/v de brimonidine ou son sel ; 1,0-1,5 % p/v de polyvinylpyrrolidone ; 0,2-0,8 % p/v de chlorure de sodium ; 0,3-0,6 % p/v d'un agent de tamponnage ; un conservateur ; un agent de contrôle du pH ; et de l'eau.
PCT/KR2011/008911 2010-12-02 2011-11-22 Composition médicinale liquide comprenant du dorzolamide et de la brimonidine pour l'ophtalmologie WO2012074237A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100121718A KR101119610B1 (ko) 2010-12-02 2010-12-02 도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물
KR10-2010-0121718 2010-12-02

Publications (2)

Publication Number Publication Date
WO2012074237A2 WO2012074237A2 (fr) 2012-06-07
WO2012074237A3 true WO2012074237A3 (fr) 2012-08-23

Family

ID=46141437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008911 WO2012074237A2 (fr) 2010-12-02 2011-11-22 Composition médicinale liquide comprenant du dorzolamide et de la brimonidine pour l'ophtalmologie

Country Status (2)

Country Link
KR (1) KR101119610B1 (fr)
WO (1) WO2012074237A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI751136B (zh) * 2016-02-22 2022-01-01 日商參天製藥股份有限公司 含多佐胺與溴莫尼定之醫藥組成物
US20190134051A1 (en) * 2017-11-06 2019-05-09 Rheostasis, Llc Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
CN111671720A (zh) * 2020-06-23 2020-09-18 苏州悦宏生物科技有限公司 一种缓解眼内异物感的滴眼液
EP4230193A1 (fr) * 2022-02-22 2023-08-23 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Composition pharmaceutique ophtalmique

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207222A1 (en) * 2006-03-01 2007-09-06 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
WO2008027340A2 (fr) * 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
US20090048261A1 (en) * 2007-08-17 2009-02-19 Arturo Jimenez Bayardo Pharmaceutical Composition for Treatment of Ocular Hypertension
US20090069345A1 (en) * 2007-09-12 2009-03-12 Arturo Jimenez Bayardo Pharmaceutically Stable Compound Consisting of Timolol, Dorzolamide and Brimonidine
KR20090053892A (ko) * 2006-07-25 2009-05-28 오스모티카 코프. 점안액

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207222A1 (en) * 2006-03-01 2007-09-06 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
KR20090053892A (ko) * 2006-07-25 2009-05-28 오스모티카 코프. 점안액
WO2008027340A2 (fr) * 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
US20090048261A1 (en) * 2007-08-17 2009-02-19 Arturo Jimenez Bayardo Pharmaceutical Composition for Treatment of Ocular Hypertension
US20090069345A1 (en) * 2007-09-12 2009-03-12 Arturo Jimenez Bayardo Pharmaceutically Stable Compound Consisting of Timolol, Dorzolamide and Brimonidine

Also Published As

Publication number Publication date
KR101119610B1 (ko) 2012-03-06
WO2012074237A2 (fr) 2012-06-07

Similar Documents

Publication Publication Date Title
NZ602685A (en) Concentrated protein formulations and uses thereof
MX2011011175A (es) Coposiciones herbicidas de alta concentracion de las sales de glifosato y de 2,4-d.
WO2014099226A3 (fr) Compositions d'hygiène personnel comprenant un halogénure d'acide aminé/triméthylglycine de zinc
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
WO2009080203A3 (fr) Dérivés d'aminobenzamide utiles en tant qu'agents pour lutter contre les parasites chez des animaux
MX2009003042A (es) Composiciones farmaceuticas acuosas auto-preservadas.
PH12013501750A1 (en) Guanidine compound
WO2010107482A3 (fr) Composition germicide
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
GEP20146015B (en) Novel acetylsalicylic acid salts
ES2720954T3 (es) Formulaciones estabilizadas de estatina
WO2012074237A3 (fr) Composition médicinale liquide comprenant du dorzolamide et de la brimonidine pour l'ophtalmologie
NZ599377A (en) Salts, aqueous liquid compositions containing salts of S-(+)-abscisic acid and methods of their preparation
ATE508740T1 (de) Mittel zur verringerung von müdigkeit
WO2008102349A3 (fr) Formulation de terbinafine
UA110577C2 (uk) Агент для боротьби з захворюваннями рослин, спосіб боротьби з захворюваннями рослин і продукт для боротьби з захворюваннями
TN2014000152A1 (en) Sustained-release preparation
WO2008073444A3 (fr) Phou (perf), commutateur-persistance impliqué dans la formation persistante en tant que cible de médicament pour bactérie persistante
WO2007092452A3 (fr) Formule et procede d'utilisation pour le traitement de l'oreille d'un animal et traitement homeopathique correspondant
NZ608406A (en) Use of storage stable viscous phospholipid depot to treat wounds
WO2008036855A3 (fr) Compositions pharmaceutiques aqueuses auto-conservées
UA111145C2 (uk) Фармацевтична композиція
WO2009017383A3 (fr) Formulation à libération prolongée comprenant un sel d'acide de metformine
WO2010031248A8 (fr) Composé de sel de thiazolium et son utilisation pour le traitement de la maladie de vieillissement des protéines
WO2012064306A3 (fr) Formulations effervescentes de rosuvastatine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11845736

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11845736

Country of ref document: EP

Kind code of ref document: A2